Do guidelines for the diagnosis and monitoring of diabetes mellitus fulfill the criteria of evidence-based guideline development?Eva Nagy
Department of Clinical Chemistry, University of Szeged, Medical Faculty, Szeged, Hungary
Clin Chem 54:1872-82. 2008
..Therefore, we assessed the methodological quality of GLs providing diagnostic recommendations for managing diabetes mellitus (DM) and explored several reasons for differences in quality across these GLs...
Screening for prostate cancer with prostate-specific antigen: beware the biasesPeter S Bunting
Gamma Dynacare Medical Laboratories, 115 Midair Court, Brampton, Ontario, Canada L6T 5M3
Clin Chim Acta 315:71-97. 2002
..The evidence relating to the use of prostate-specific antigen (PSA) as a screening test is a highly controversial, as demonstrated by the lack of agreement among experts. There may be biases associated with various studies...
- Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study
Jacek A Kopec
Department of Health Care and Epidemiology, University of British Columbia, Vancouver, Canada
J Urol 174:495-9; discussion 499. 2005
..There is limited evidence that screening is effective in reducing mortality from prostate cancer. In the current study we determined if screening with PSA reduces the risk of metastatic prostate cancer...
- A reliable coding system to define screening prostate-specific antigen tests was developed in a case-control study
Peter S Bunting
Division of Biochemistry, Department of Pathology and Laboratory Medicine, University of Ottawa, Ontario, Canada
J Clin Epidemiol 58:639-44. 2005
..To establish the reliability of a coding system for screening and diagnostic prostate-specific antigen (PSA) testing from patient charts...
- Has there been a change in practice of screening for prostate cancer with prostate-specific antigen in Ontario?
Peter S Bunting
Department of Pathology and Laboratory Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, ON, K1Y 4E9, Canada
Clin Biochem 37:898-903. 2004
..To determine whether there has been a change in the rate of screening in Ontario in 2002 compared to 1995...
- Laboratory survey of prostate-specific antigen testing in Ontario updated
Peter S Bunting
Department of Pathology and Laboratory Medicine, The Ottawa Hospital, Ottawa, ON, Canada
Clin Biochem 37:418-21. 2004
- Intraindividual variation of PSA, free PSA and complexed PSA in a cohort of patients with prostate cancer managed with watchful observation
Peter S Bunting
Department of Clinical Pathology, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
Clin Biochem 35:471-5. 2002
..To determine the intraindividual variation of prostate-specific antigen (PSA) isoforms in prostate cancer patients managed conservatively with watchful observation...
- Reliability of point-of-care testing for glucose measurement in critically ill adults
Salmaan Kanji
Department of Pharmacy, The Ottawa Hospital, Ottawa, Canada
Crit Care Med 33:2778-85. 2005
....
- Conflict between guideline methodologic quality and recommendation validity: a potential problem for practitioners
Joseph Watine
Laboratoire de biologie polyvalente, Centre Hospitalier Général de Rodez, Rodez, France
Clin Chem 52:65-72. 2006
....
- [Mass screening for colorectal cancer with the guaiac fecal occult blood test: possible population benefits, proven individual risks]
Joseph C Watine
Presse Med 37:363-6. 2008
- Mass colorectal cancer screening: methodological quality of practice guidelines is not related to their content validity
Joseph C Watine
Laboratoire de biologie polyvalente, Centre Hospitalier General, Rodez, France
Clin Biochem 41:459-66. 2008
..We assessed whether or not there is a link between methodological quality and recommendation validity in GLs for the use of fecal occult blood test (FOBT) as a screening test for colorectal cancer (CRC) in the average-risk population...
